• 1
    Kunches L., Craven D., Werner B. Seroprevalence of hepatitis B virus and delta agent in parenteral drug abusers. Immunogenicity of hepatitis B vaccine. Am J Med. 1986; 81(4): 5915.
  • 2
    Mandelli C., Cesana M., Ferroni P., et al. HBV, HDV and HIV infections in 242 drug addicts: two-year follow-up. Eur J Epidemiol. 1988; 4(3): 31821.
  • 3
    Levine O., Vlahov D., Koehler J., et al. Seroepidemiology of hepatitis B virus in a population of injecting drug users. Am J Epidemiol. 1995; 142: 33141.
  • 4
    Garfein R., Vlahov D., Galai N., et al. Viral infection in short-term injection drug users: the prevalence of the Hepatitis C, Hepatitis B, Human Immunodeficiency, and Human T-Lymphotropic viruses. Am J Public Health. 1996; 86: 65561.
  • 5
    Crofts N., Aitken C. Incidence of blood borne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990–1995. Med J Aust. 1997; 167: 1720.
  • 6
    Lin M., Roche P., Spencer J., et al. Australia's notifiable disease status, 2000. Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell. 2002; 26: 118203.
  • 7
    Mangtani P., Kovats S., Hall A. Hepatitis B vaccination policy in drug treatment services. Br Med J. 1995; 311: 1500.
  • 8
    National Health and Medical Research Council.The Australian Immunisation Handbook. 6th ed. Canberra ( Aust ) : AGPS; 1997.
  • 9
    Anderson B., Bodsworth N., Rohrsheim R., et al. Hepatitis B virus infection and vaccination status of ‘high risk’ people in Sydney: 1982–1991. Med J Aust. 1994; 161: 36871.
  • 10
    Fardell K. Audit of Hepatitis B Vaccination Program — Royal Adelaide Hospital [STD Information on the Internet]. Adelaide ( Aust ) : Royal Adelaide Hospital, Sexually Transmitted Diseases Services; 1999. Available from: http:www.stdservices.on.netstdhepatitis_bvaccination_audit.htm [cited 2004 September 2].
  • 11
    Lamagni TL, Davison KL, Hope VD, et al. Poor hepatitis B vaccine coverage in injecting drug users: England, 1995 and 1996. Commun Dis Public Health. 1999; 2(3): 1747.
  • 12
    Marchou B., Picot N., Chavanet P., et al. Three-week hepatitis B vaccination provides protective immunity. Vaccine. 1993; 11(14): 13835.
  • 13
    Bock HL, Loscher T., Scheiermann N., et al. Accelerated Schedule for Hepatitis B Immunization. J Travel Med. 1999; 2(4): 21317.
  • 14
    Pallecaros A., Robinson A. Hepatitis B vaccination. Br Med J. 1996; 312: 777.
  • 15
    Wong VK, Shapiro R. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic. Pediatr Infect Dis J. 1994; 13: 936.
  • 16
    Kuo I., Sherman SG, Thomas DL, et al. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend. 2004; 73(1): 6978.
  • 17
    Success Works. Young People and Drugs Needs Analysis. Melbourne ( Aust ) : Drug Treatment Services Unit. Aged, Community and Mental Health Division, Department of Human Services; 1998.
  • 18
    Murray P., Brennan C., O'Neill S., et al. Hepatitis B vaccination among high-risk adolescents and adults- San Diego, California, 1998–2001. MMWR Morb Mortal Wkly Rpt. 2002; 51(28): 61821.
  • 19
    Wilkinson SE, Morath M., Bennett DL, et al. Accelerated schedule of hepatitis B vaccination in high-risk youth. J Paediatr Child Health. 1996; 32(1): 6062.
  • 20
    Smith G., Fischer D., Cox H., et al. Street-Linked Therapy. J Strategic Systemic Therapies. 1989; 8(2,3): 2635.
  • 21
    Reid G., Crofts N., Hocking J. Needs Analysis for Primary Health Care Among the Street Drug-using Community in Footscray. Melbourne ( Aust ) : The Centre for Harm Reduction, Macfarlane Burnet Centre for Medical Research; 2000.
  • 22
    Lum PJ, Ochoa, KC, Hahn JA, et al. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: The UFO Study. Am J Public Health. 2003; 93(6): 91923.
  • 23
    Marchou B., Excler, JL, Bourderioux C., et al. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. J Infect Dis. 1995; 172(l): 25860.
  • 24
    Bosnak M., Dikici B., Bosnak V., et al. Accelerated hepatitis B vaccination schedule in childhood. Pediatr Int. 2002; 44(6): 6635.
  • 25
    Nothdurft HD, Dietrich M., Zuckerman JN, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine. 2002; 20(7–8): 115762.
  • 26
    Rumi M., Colombo M., Romeo R., et al. Suboptimal response to hepatitis B vaccine in drug users. Arch Intern Med. 1991; 151(3): 5748.